Trillium Therapeutics Inc.
TRIL
TRIL was delisted on the 16th of November, 2021.
26 hedge funds and large institutions have $53.1M invested in Trillium Therapeutics Inc. in 2017 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 4 closing their positions.
150% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 4
102% more capital invested
Capital invested by funds: $26.2M → $53.1M (+$26.8M)
50% more call options, than puts
Call options by funds: $256K | Put options by funds: $171K
30% more funds holding
Funds holding: 20 → 26 (+6)
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCMC
Matrix Capital Management Company
Portsmouth,
New Hampshire
|
+$18M |
| 2 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$1.66M |
| 3 |
Renaissance Technologies
New York
|
+$1.3M |
| 4 |
AG
Artal Group
Luxembourg
|
+$1.24M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$906K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$2.21M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$1.21M |
| 3 |
AIC
AWM Investment Company
New York
|
-$915K |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$414K |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$133K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Janus Henderson Group
London,
United Kingdom
| – | -$2.21M | -429,262 | Closed |
|
|
SAM
27
Sectoral Asset Management
Montreal,
Quebec, Canada
| – | -$1.21M | -234,248 | Closed |
|
28
UBS Group
Zurich,
Switzerland
| – | -$6K | -1,230 | Closed |
|
29
Bank of America
Charlotte,
North Carolina
| – | -$2K | -400 | Closed |
|
30
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| – | +$464 | +56 | New |
|
TRIL Hedge Fund Activity: Q4 2017 in Review
26 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Trillium Therapeutics Inc. (TRIL) for Q4 2017, worth a combined $53.1M — up 102% from $26.2M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new TRIL positions and 4 closed out — a net gain of 6 holders — while 7 added to existing stakes and 6 trimmed.
The largest buyer was Matrix Capital Management Company, opening a new position worth an estimated $18M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $2.21M sold.
- 26 institutional investors held Trillium Therapeutics Inc. (TRIL) as of Q4 2017, up from 20 in Q3 2017.
- Funds reported $53.1M of Trillium Therapeutics Inc. stock for Q4 2017, up 102% quarter-over-quarter.
- 10 funds opened new Trillium Therapeutics Inc. positions in Q4 2017 and 4 closed out, a net change of +6 holders.
- The largest Trillium Therapeutics Inc. buyer in Q4 2017 was Matrix Capital Management Company, an estimated $18M added.
- The largest Trillium Therapeutics Inc. seller in Q4 2017 was Janus Henderson Group, an estimated $2.21M sold.
Based on aggregated 13F filings for Q4 2017.